Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-
Alumis Completes Patient Enrollment in Global LUMUS Phase 2b Trial of ESK-001, Next-Generation Oral TYK2 Inhibitor for SLE, data in 3Q 2026
-
Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary
-
Alumis completed enrollment of Phase 3 ONWARD clinical program of ESK-001, a next-generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis
-
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
-
Alumis Stockholders Approve Merger with ACELYRIN
-
Alumis and Kaken Pharmaceutical collaborate for oral next-generation TYK2 inhibitor ESK-001 in dermatology in Japan
-
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
-
Alumis to Present at Leerink's 2025 Global Healthcare Conference
-
ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025